Tafasitamab - Incyte Corporation
Alternative Names: anti-CD19 MAb XmAb5574; anti-CD19 MoAb XmAb5574; ICP-B04; INCMOR0208; Minjuvi; Monjuvi; MOR 208; MOR-00208; Tafasitamab-cxix; XENP-5574; XmAb-5574Latest Information Update: 28 Jun 2025
At a glance
- Originator Xencor
- Developer Incyte Corporation; InnoCare Pharma; Knight Therapeutics; MorphoSys; Pfizer; University Medical Center of the Johannes Gutenberg University Mainz; Xencor
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Diffuse large B cell lymphoma
- Registered Follicular lymphoma
- Phase III Marginal zone B-cell lymphoma
- Phase II B-cell lymphoma; Chronic lymphocytic leukaemia; Haematological malignancies; Non-Hodgkin's lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 28 Jun 2025 No recent reports of development identified for phase-I development in Diffuse large B cell lymphoma(Combination therapy, First-line therapy) in Japan (IV, Infusion)
- 28 Jun 2025 No recent reports of development identified for phase-I development in Diffuse large B cell lymphoma(Combination therapy, Newly diagnosed) in Austria (IV, Infusion)
- 28 Jun 2025 No recent reports of development identified for phase-I development in Diffuse large B cell lymphoma(Combination therapy, Newly diagnosed) in Belgium (IV, Infusion)